Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury.
Level 5 - mechanism / opinion, no new human data
Animal research without human clinical data
PubMed 19903499 · doi:10.1016/j.regpep.2009.11.005
What was done
Researchers evaluated the effect of stable gastric pentadecapeptide BPC 157 (10 microg/kg or 10 ng/kg) in rats with transected sciatic nerves. BPC 157 was administered shortly after injury via intraperitoneal, intragastric, or local application at the anastomosis site, or directly into a nerve tube following a 7 mm nerve segment resection. Outcomes evaluated included clinical autotomy, histomorphometry (fiber density, size, myelin thickness, and blood vessel presentation), electrophysiology (EMG at 1 to 2 months post-injury), and functional motor recovery (sciatic functional index assessed weekly).
What was found
The abstract reports that BPC 157-treated rats exhibited absent autotomy, faster axonal regeneration, increased diameter and density of myelinated fibers, increased myelin sheath thickness, enhanced blood vessel presentation, increased motor action potentials on EMG, and improved sciatic functional index scores. The abstract provides no specific numerical values, exact group sizes, or statistical confidence intervals.
Why it matters
This study suggests that systemic or local administration of BPC 157 may promote peripheral nerve regeneration and functional recovery in a rodent model of severe nerve transection.
Limits
Findings are limited to an animal model and cannot be directly translated to human clinical outcomes. The abstract does not report animal sample sizes, specific quantitative measurements, baseline control values, or statistical significance thresholds.
Cited by
- supports Animal studies show BPC-157 promotes fibroblast recruitment and tissue repair in models of Achilles tendon rupture and sciatic nerve injury.